

Department of Medical Health and Family Welfare Government of Uttar Pradesh

CONTENT

Sl No.	Торіс	Page Number
1.	Introduction	3
2.	Antimicrobial Resistance	3
3.	Super bugs	3
4.	Hospital Acquired Infections (HAI)	4
5.	Classification	4
6.	Standard Usage: Presumptive Therapy for Adult Patients Suspected Of Infection	5 - 32
	Gastrointestinal & Intra-Abdominal Infections	5
	Central Nervous System Infections	9
	Cardiovascular Infections	10
	Skin & Soft Tissue Infections	13
	Respiratory Tract Infections	15
	Urinary Tract Infections	17
	 Obstetrics and Gynecological Infections 	19
	Bones and Joint Infections	29
	Fungal Infections	31
	Surgical Antimicrobial Prophylaxis	31
7.	Good Practice	33
8.	Monitoring Sheets	34
9.	References	35

Introduction

Antimicrobial resistance is a broader term, encompassing resistance to drugs to treat infections caused by other microbes as well, such as parasites (e.g. malaria), viruses (e.g. HIV) and fungi (e.g. Candida). Antimicrobial resistance has been observed and reported with practically all the newly discovered antimicrobial molecules to date. Antimicrobial resistance makes the treatment of patients difficult, costly and sometimes impossible.

The emergence of antimicrobial resistance in pathogens has become a matter of great public health concern. Antimicrobial resistance is well recognized as a global threat to human health. Infections caused by antimicrobial-resistant micro-organisms in hospitals are associated with increased morbidity, mortality and healthcare costs.

Antimicrobial Resistance

Antimicrobial resistance occurs when microorganisms such as bacteria, viruses, fungi, and parasites change in ways that render the medications used to cure the infections they cause ineffective. Antimicrobial resistance is the broader term for resistance in different types of microorganisms and encompasses resistance to antibacterial, antiviral, antiparasitic and antifungal drugs.

Antimicrobial resistance is closely linked to inappropriate antimicrobial use. It is estimated that 50% or more of hospital antimicrobial use is inappropriate. There is a need for increased education and awareness about antimicrobial resistance among the public and health-care professionals. One needs to develop and improve the surveillance system for antimicrobial resistance and infectious diseases in general, particularly through improved linkage of data. Nothing will work unless we improve diagnostic testing to ensure more tailored interventions and respond to the opportunities afforded by advances in genomic technologies and point of care testing.

Antimicrobial resistance occurs naturally but is facilitated by the inappropriate use of medicines, for example using antibiotics for viral infections such as cold or flu, or sharing antibiotics. Lowquality medicines, wrong prescriptions, and poor infection prevention and control also encourage the development and spread of drug resistance. Lack of government commitment to address these issues, poor surveillance and a diminishing arsenal of tools to diagnose, treat and prevent also hinder the control of antimicrobial drug resistance.

Superbugs

When the microorganisms become resistant to most antimicrobials they are often referred to as "superbugs". This is a major concern because a resistant infection may kill, can spread to others, and imposes huge costs to individuals and society.

Resistant bacteria that cause pneumonia, urinary tract infections and skin infections are just a few of the dangers we now face.

Antibiotic resistance is a naturally occurring phenomenon that can be slowed, but not stopped. Over time, bacteria adapt to the drugs that are designed to kill them and change to ensure their survival. This makes previously standard treatments for bacterial infections less effective, and in some cases, ineffective.

Hospital Acquired Infections (HAI)

HAI occur worldwide and affect both developed and resource-poor countries. Infections acquired in health care settings are among the major causes of death and increased morbidity among hospitalized patients. They are a significant burden both for the patient and for public health.

Many factors promote infection among hospitalized patients: decreased immunity among patients; the increasing variety of medical procedures and invasive techniques creating potential routes of infection; and the transmission of drug-resistant bacteria among crowded hospital populations, where poor infection control practices may facilitate transmission.

Classification

Classified into different types based on different classification modes.

The first classification is according to the spectrum: The spectrum means the number of organisms affected by the same drug.

Broad-Spectrum Antibiotics: The Broad-spectrum antibiotics affect several types of bacteria and fungi and it is usually used where the specific type of the microorganism is unknown.

Narrow spectrum antibiotics: Narrow spectrum antibiotics are used only when we know the specific type of microorganism. These are more effective on specific microorganisms but less effective on others.

The second classification is according to the type of action of antibiotics. Antibiotics can be divided into two classes based on their mechanism of action.

Bactericidal antibodies: They kill bacteria by inhibiting cell wall synthesis. Examples include:Beta-lactam antibiotics (penicillin derivatives (penams),cephalosporins (cephems), monobactams,and carbapenems) and vancomycin. Also bactericidal are daptomycin, fluoroquinolones, metronidazole, nitrofurantoin, co-trimoxazole, telithromycin.

Bacteriostatic antibiotics: They limit the growth of bacteria by interfering with bacterial protein production, DNA replication, or other aspects of bacterial cellular metabolism. They must work together with the immune system to remove the microorganisms from the body. However, there is not always a precise distinction between them and bactericidal antibiotics. High concentrations of some bacteriostatic agents are also bactericidal, whereas low concentrations of some bacteriocidal agents are bacteriostatic.

This group includes tetracyclines, sulfonamides, spectinomycin, trimethoprim, chloramphenicol,macrolides, and lincosamides.

4 Another classification is according to the **chemical structure**:

Penicillins such as penicillin and amoxicillin

Cephalosporins such as cephalexin (Keflex)

Macrolides such as erythromycin (E-Mycin), clarithromycin (Biaxin), and azithromycin (Zithromax)

Fluoroquinolones such as ofloxacin (Cipro), levofloxacin (Levaquin), and ofloxacin (Floxin)

Sulfonamides such as co-trimoxazole (Bactrim) and trimethoprim (Proloprim)

Tetracyclines such as tetracycline (Sumycin, Panmycin) and doxycycline (Vibramycin)

Aminoglycosides such as gentamicin (Garamycin) and tobramycin (Tobrex)

Standard Usage: Presumptive Therapy for Adult Patients Suspected Of Infection

- **Gastrointestinal & Intra-Abdominal Infections**
- Central Nervous System Infections
- **4** Cardiovascular Infections
- **4** Skin & Soft Tissue Infections
- **4** Respiratory Tract Infections
- **Urinary Tract Infections**
- Obstetrics and Gynaecological Infections
- **H** Bones and Joint Infections
- **4** Fungal Infections
- **Surgical Antimicrobial Prophylaxis**

GASTROINTESTINAL & INTRA-ABDOMINAL INFECTIONS

Condition	Likely Causative Organisms	Empiric (presumptive) antibiotics/First Line	Alternative antibiotics/Second Line	Comments
Acute	Viral,	None	None	Rehydration
Gastroenteritis	Entero-toxigenic & Entero- pathogenic E. coli			(oral/IV) essential

Food poisoning	S. aureus,			
	cereus,			
	botulinum			
Cholera	V.cholerae	Doxycycline 300mg Oral stat	Azithromycin 1gm Oral stat or Ciprofloxacin 500mg BD for 3 days	Rehydration (oral/IV) is essential
		Azithromycin Oral in children (20mg/kg) and pregnant women (1g)		Antibiotics are adjunctive therapy.
Bacterial	Shigella sp.,	Ceftriaxone 2gm IV	Azithromycin 1g	For
dysentery	Campylobacter, Non- typhoidal salmonellosis	OD for 5 days or oral cefixime 10-15 mg/kg/day x 5 days	OD x 3days	Campylobacter the drug of choice is azithromycin.
	Shiga toxin	Antibiotic Treatment		Antibiotic
	producing E. coli	not recommended.		use associated with development of hemolytic uremic syndrome.
Amoebic dysentery	E. histolytica	Metronidazole 400mg Oral TDS for 7-10 days	Tinidazole2gmOral OD for 3 days	Add diloxanide furoate 500 mg TDS for 10d
Giardiasis	Giardia lamblia	Metronidazole 250- 500mg oral TID x 7-10 d	Tinidazole 2 gm oral x 1 dose	
Enteric fever	S.Typhi, S.Paratyphi A	Outpatients: Cefixime 20mg/kg/day for 14 days or Azithromycin 500 mg BD for 7 days. <u>Inpatients:</u> Ceftriaxone 2 g IV BDfor 2 weeks +/-Azithromycin 500 mg BD for 7 days	Cotrimoxazole 960 mg BD for 2 weeks	Majority of strains arenalidixic acid resistant. Ceftriaxone to be changed to oral cefixime when patient is afebrile to finish total duration of 14days.
Biliary tract infections (cholangitis, cholecystitis)	Enterobacteriaceae (E.coli, Klebsiella sp.)	Ceftriaxone 2gm IV OD or Piperacillin- Tazobactam 4.5gm IV 8 hourly or Cefoperazoe- Sulbactam 3gm IV 12hourly	Imipenem500mgIV 6hourlyororMeropenemIV 8hourlyFor 7-10 days	Surgical or endoscopic intervention to be considered if there is biliary obstruction. High

Hospital acquired diarrhea	C. difficile	For 7-10 days Metronidazole 400 mg oral TDSfor 10 days	Severe disease:start Vancomycin 250 mg oral 6h empirically.	prevalence of ESBL producing E.coli, Klebsiella sp.strains. De- escalate therapy once antibiotic susceptibility is known.
Spontaneous bacterial Peritonitis	Enterobacteriacea e (E.coli, Klebsiella sp.)	Cefotaxime 1-2 gm IV TDS or Piperacillin- Tazobactam 4.5gm IV 8 hourly or Cefoperazone- Sulbactam 3gm IV 12h	Imipenem 500 mg IV 6hourly or Meropenem 1gm IV 8hourly	Descalate to Ertapenem 1 gm IV OD for 5-7 days once the patient improves
Secondary peritonitis, Intra- abdominal abscess/ GI perforation	Enterobacteriaceae (E.coli, Klebsiella sp.), Bacteroides (colonic perforation), Anaerobes	Piperacillin- Tazobactam 4.5gm IV 8 hourly or Cefoperazone- Sulbactam 3gm IV 12hourly in severe infections In very sickpatients, if required, addition of cover for yeast (fluconazole iv 800 mg loading dose day 1, followed by 400 mg 2 nd day onwards) & and for Enterococcus (vancomycin /teicoplanin) may be	Imipenem 1g IV 8hourly or Meropenem 1gm IV 8hourly or Doripenem 500 mg TDS or Ertapenem 1 gm IV OD	Source control is important to reduce bacterial load. If excellent source control – for 5-7 days; other wise 2- 3 weeks suggested.

		contemplated		
Pancreatitis Mild- moderate		No antibiotics		
Post necrotizing pancreatitis: infected pseudocyst; pancreatic abscess	Entrobacteriaceae , Enterococci, S. aureus, S. epidermidis, anaerobes, Candida sp.	Piperacillin- Tazobactam 4.5 gm IV 8 hourly empirically or Cefoperazone- Sulbactam 3gm IV 8 hourly in severe infections	Imipenem- Cilastatin500mgIV 6hourly0or1gmIV 8hourly0orDoripenemJU 8h500mgIV 8h	Duration of treatment is based on source control and clinical improvement
		In very sick patients, if required, addition of cover for yeast (fluconazole iv 800 mg loading dose day 1, followed by 400 mg 2 nd day onwards) & and for Enterococcus (vancomycin /teicoplanin) may be contemplated For 7-10 days		
Diverticulitis Mild-	Gram-Negative Bacteria	Amoxycillin- Clavulanate 625mg	Ciprofloxacin + Metronidazole for	
OPD treatment	Anaerobes	TDS for 7 days	7 days	
Diverticulitis	Gram- Negative	Ceftriaxone 2gm IV	7 duys	BL-BLI agents
moderate	Bacteria	OD +metronidazole		have very good
	Anaerobes	500 mg IV TDS or		anaerobic
				cover, so
		Piperacillin-		no need to add
		Tazobactam 4.5 gm IV		metronidazole.
		8 hourly empirically		
		or		
		Cefoperazoe-		
		Sulbactam 3gm IV 8		
		hourly		
Diverticulitis	Gram- Negative	Meropenem 1gm IV		Duration based
a				on
Severe	Bacteria	8hrly or Imipenem		improvement
	Anaerobes	Cilastatin 500mg IV		
		6		
		hourly		

Liver Abscess	Polymicrobial	Amoxycillin-	Piperacillin-	Ultrasound
		clavulanate/ 3rd	Tazobactam IV	guided
		generation		drainage
		cephalosporin		indicated
		+		In large
		Metronidazole		abscesses,
		500mg I.V.TID /		Signs of
		800mg oral TID for		imminent
		2 weeks		rupture and no
				response to
				Medical
				treatment.

<u>CENTRAL NERVOUS SYSTEM INFECTIONS</u>

Condition	Likely Causative Organisms	Empiric antibiotics (presumptive antibiotics)	Alternative antibiotics	Comments
Acute bacterial Meningitis	S. pneumoniae, H.influenzae, Neisseria meningititidis	Ceftriaxone 2 g IV 12hourly/ Cefotaxime 2 g IV 4-6hourly 10-14 days treatment	Chloramphe nicol if patient is allergic to penicillin	Antibiotics should be started as soon as the possibility of bacterial meningitis becomes evident, ideally within 30 minutes. Do not wait for CT scan or LP results. No need to add vancomycin as primary agent, as ceftriaxone resistant <i>Pneumococcus</i> is not common in India. <i>Listeria</i> is also rare in India and so ampicillin is also not indicated Adjust therapy once pathogen and susceptibilities are known.
Meningitis- Post- neurosurgeryor Penetratinghead trauma	Staphylococcus epidermidis, Staphylococcus aureus, Propionibacterium acnes, Pseudomonas aeruginosa,	Meropenem 2gm IV 8 hourly AND Vancomycin 15mg/kg IV 8 hourly For 14 days.		May need intra ventricular therapy in severe cases

	Acinetobacter baumanii			
Meningitis with basilar	S.pneumoniae,	Ceftriaxone 2gm IV 12		Dexamethasone
skull fractures	H. influenzae	hourly		0.15mg/kg IV 6
		For 14 days		hourlyfor 2-4day (1st
				dose with or before
				first antibiotic dose)
Brain abscess, Subdural empyema	Streptococci, Bacteroides, Enterobacteria-ceae, S.aureus	Ceftriaxone 2 gm IV 12hourly or Cefotaxime 2 gm IV 4-6hourly	Meropenem 2gm IV 8hourly	Aspergillus, Mucor If abscess <2.5cm & patient neurologically stable await response to antibiotics. Otherwise, conside aspiration/surgical drainageand modify antibiotics as pe sensitivity o aspirated/drained
		AND		secretions.
		Metronidazole 1 gm IV 12hourly		
		gill IV 12hourlyDurationoftreatmenttodecidedbyclinical&radiologicalresponse,minimumtwomonths required.		

<u> CARDIOVASCULAR INFECTIONS</u>

Condition	Likely causa	tiveEmpiric antibio	oticsAlternative	Comments
	Organism	(presumptive	antibiotics	
		antibiotics)		

Infective	Viridans	Penicillin G 20MUVancomycin If patient is stable
Endocarditis:	Streptococci, o	therIV 15mg/kg IV 12 <i>ideally waitbloo</i>
	Streptococci, Enterococci	divided doses, 4 hourly <i>cultures</i> . hourly 12
(awaiting cultures) Indolent		or hourly)//teicplan Antibiotic choice as pe
		Ampicillin 2gm iv 4n [12] hourly x 3
		doses followedGuidance from
		by 6 - 12 mgInfectious diseas
		AND once daily IVspecialist or clinica
		depending upon microbiologist i
		severity +recommended
		Gentamicin 1mg/kg
		im or iv 8h
		IV 8 hourly
		Duration: 4-6 weeks weeks
		or Daptomycin
		6mg/kg IV
		once a day
		Duration: 4-6 weeks

Infective	S.aureus	Vancomycin 25- 30	Daptomycin	Modify antibiotics
Endocarditis:		mg/kg loading	6mg/kg IV once	based on culture results
Native valve	(MSSA or MRSA)	followed by 15-20	a day	and complete 4-6 weeks
awaiting	Risk for gram-	mg/kg IV 12 hourly		of antibiotics
1		(maximum 1gm	AND	
	8	12hourly)/teicoplan	Meropenem	
In Severe Sepsis		in 12mg/kg IV 12	1gm IV q8h	
		hourly x 3 doses		
		followed by 6 -12 mg		
		once daily IV	Dynation, 16	
		depending upon	Duration: 4-6	
		severity AND	weeks	
		Meropenem 1gm IV		
		8hDuration:4-6		
		weeks		

Infective	Vancomycin	Daptomycin	Antibiotic choice as
Endocarditis:	15mg/kg IV 12	can be used in	per sensitivity.
Prosthetic Valve	hourly (maximum	place of	Guidance from
awaiting Cultures	1gm 12	Vancomycin/	Infectious disease
	hourly)/teicoplan in 12mg/kg IV 12 hourly x 3 doses followed by 6 -12 mg once daily IV depending upon severity + Gentamicin	Teicoplanin for patients unresponsive to	specialist or microbiologist is recommended.
	1mg/kg q12h IV	resistant isolates	

SKIN & SOFT TISSUE INFECTIONS

Condition	Likely Causative	Empiric antibiotics	Alternative	Comments
	Organisms	(presumptive antibiotics)	antibiotics	
Cellulitis	Streptococcus pyogenes(common), S.aureus		600-900mg IV TDS	Treat for 5-7 days.
Furunculosis	S.aureus	Amoxicillin- Clavulanate 1.2gm IV/Oral 625 TDS or Ceftriaxone 2gm IV OD Duration – 5-7 days	TDS	Get pus cultures before starting antibiotics

Vecrotizing	Streptococcus	Piperacillin-	Imipenem	1gEarly	surgica
fasciitis	pyogenes, S. aureu	s, Tazobactam 4.5gm	IV8hourly	interventi	on crucial
	anaerobes,	IV			
	Enterobacteriaceae		or		
	(polymicrobial)	6hourly	Meropenem 1	gm	
		or Cefoperazone	-IV 8hourly		
		Sulbactam 3gm IV 12hourly	AND		
			Clindamycin		
			600-900mg IV		
		AND	TDS/linezolid		
			600 mg IV		
		Clindamycin 600-	-BD/daptomycir	1	
		900mg IV 8	6mg/kg/day		
		hourly			
		Duration depends or the	ı		
		progress			

<u>RESPIRATORY TRACT INFECTIONS</u>

	8	-	Alternative antibiotics	Comments
Community acquired			Piperacillin-	If MRSA is a concern,
Pneumonia	H.influenzae, Legionella, E.coli, Klebsiella sp., S.aureus	<u>moderate</u> <u>cases</u> Amoxycillin- 500mg-1 g TDS oral. If IV indicated, amoxycillin-	Tazobactam 4.5gm IV 6 hourly or Imipenem 1g IV 6hourly or Cefoperazone- Sulbactam 3gm IV 12 hourly	add Linezolid 600mg IV/Oral BD If atypical pneumonia suspected, Doxycycline 100mg bd
	E.coli, Klebsiella sp., Pseudomonas aeruginosa, S.aureus, anaerobes	Tazobactam 4.5gm IV 6hourly	8hourly	3-4 weeks treatment required

Acute pharyngitis	Viral	None required		As most cases are viral no antimicrobial therapy required
	Group Α β- hemolytic	Oral Penicillin v	In case of penicillin	Antibiotics are recommended
	Streptococci	500mg BD	allergy:	to reduce transmission rates
	(GABHS),	or	Azithromycin	and prevention of long term
	1 /	Amoxicillin 500 mg	500mg OD for 5	sequaelae such as rheumatic
	Streptococcus,	Oral TDS for 10	days	fever
			or	
			Benzathine penicillin 12 lac	
			units IM stat	
Ludwig's angina Vincent's angina	(Cover oral anaerobes)	600 mg IV 8	1	Duration based on improvement
Acute bacterial rhinosinusitis	S. pneumoniae,	clavulanate	Moxifloxacin 400mg OD for 5- 7days	
Acute bronchitis		Antibiotics not required	-	-
exacerbation of	H. influenzae	clavulanate	Azithromycin 500 mg oral OD × 3 days	

URINARY TRACT INFECTIONS

Asymptomatic bacteriuria NOT to be treated except pregnant women and immunocompromised patients. All cases of dysuria may not be UTI. Refer to Obstetrics and gynaecology infections for treatment of asymptomatic bacteriuira in pregnant women.

	0	-	Alternative antibiotics	Comments
Acute uncomplicated	E.coli,	Nitrofurantoin	Cefuroxime 250 mg	Get urine cultures before
	saphrophyticus(in	7 days or Cotrimoxazole 960mg BD for		antibiotics & modify therapy based on sensitivities.
	Staphylococcus saphrophyticus (in sexually active young women), Klebsiella pneumoniae, Proteus mirabilis	OD IM/IV or Gentamicin 7 mg/kg/day OD (Monitor renal	6 hourly or Cefoperazone- Sulbactam 3g IV 12 hourly or Ertapenem 1 g IV OD	

Complicated	Escherichia coli,	Piperacillin-	Imipenem 1g IV 8	Get urine cultures before
Pyelonephritis	Klebsiella	Tazobactam	hourly	antibiotics & switch to a
	pneumonia, Proteus	-	or	narrow spectrum agent
		hourly		based on sensitivities.
	Pseudomonas aeruginosa,	or	Meropenem 1gm IV 8 hourly	Treat for 10- 14 days.
	Enterococcus sp.	Amikacin 1 g		
		OD IV		De-escalate to Ertapenem 1 gm IV OD,
		or Cefoperazone-		if Imipenem/meropenem initiated.
	4	Sulbactam 3gm IV 12 hourly		Monitor renal function if aminoglycoside is used.
Acute prostatitis	Enterobacteriaceae (E.coli, Klebsiella sp.)	Co-trimoxazole 960 mg BD.	Piperacillin- Tazobactam 4.5gn IV 6	Get urine and prostatic massagecultures before antibiotics & switch to narrow spectrum agent based on sensitivities and then treat total for 3- 4 weeks. Use Ciprofloxacin (if sensitive)
			or Meropenem 1gm IV 8 hourly	7

<u>OBSTETRICS AND GYNAECOLOGICAL INFECTIONS</u>

Fluoroquinolones are contraindicated in 1st trimester.

Cotrimoxazole is contraindicated in 1st trimester.

Doxycycline is not recommended in nursing mothers. If need to administer doxycycline discontinuation of nursing may be contemplated.

Infections	Primary treatment (presumptive antibiotics)	Alternate treatment	Remarks
Asymptomatic	Nitrofurantoin 100	Oral	Screen in 1st trimester. Can cause pylonephritis in upto 25% of all pregnant women.
Bacteriuria	mg Oral, BD for 7	cephalosporins,	30 % Chance of recurrence after empirical therapy 1.
> 1,00,000 cfu/ ml of	days	TMP-SMX or TMP	Few direct effects, uterine hypo perfusion due to
bacteria of same	or Amoxicillin 500	alone	maternal anemia dehydration, may cause fetal cerebral hypo perfusion.
species in 2 urine	mg Oral BD		2. LBW,
cultures obtained 2-7 days apart. Treat as per sensitivity result for 7 days.	x 7-10 days .		prematurity,premature labour, hypertension, preeclampsia, maternal anemia, and amnionitis. Need to document pyuria (Pus cells > 10/HPF)

Group E	B Group	BIV Penicillin G	Cefazolin 2 gm IV	Prevalance very low so the
streptococcal	Streptococci			prophylaxis may be required
Disease,		(Loading dose)	then 1 gm TID	only on culture documented
Prophylaxis and	1	then		report Associated with high
Freatment		2.5 -3 million		risk of pre-term labour,stil
		units IV QID		birth,neonatal sepsis
		(1 1 1)		
		until delivery.	Clindamycin 900	
		or	mg IV TID or	
		A	vancomycin IV or	
		-	teicoplanin for	
		-	penicillin allergy	
		Loading dose)		
		then 1 gm QID until		
		unun		
		delivery		
Chorioamnionit is	negative bacil ureaplasma and	lli, chlamydiae, anaerobes, usually	teicoplanin and	unfavourable neurologi
	negative bacil		teicoplanin and cefoperazone- sulbactum	1
	negative bacil ureaplasma and		teicoplanin and cefoperazone- sulbactum	unfavourable neurologi outcome, lesser risk to term
	negative bacil ureaplasma and		teicoplanin and cefoperazone- sulbactum	unfavourable neurologi outcome, lesser risk to term infants.
	negative bacil ureaplasma and Polymicrobial		teicoplanin and cefoperazone- sulbactum If patient is not in sepsis then IV	unfavourable neurologi outcome, lesser risk to term infants.
	negative bacil ureaplasma and Polymicrobial Bacteroides, Prevotella	anaerobes, usually Ampicillin 500	teicoplanin and cefoperazone- sulbactum If patient is not in sepsis then IV Ampicillin	unfavourable neurologi outcome, lesser risk to term infants.
	negative bacil ureaplasma and Polymicrobial Bacteroides, Prevotella	anaerobes, usually	teicoplanin and cefoperazone- sulbactum If patient is not in sepsis then IV Ampicillin	unfavourable neurologi outcome, lesser risk to term infants.
is	negative bacil ureaplasma and Polymicrobial Bacteroides, <i>Prevotella</i> <i>bivius</i> ,	anaerobes, usually Ampicillin 500 mg QID + Metronidazole	teicoplanin and cefoperazone- sulbactum If patient is not in sepsis then IV Ampicillin Ceftriaxone 2g IV	unfavourable neurologi outcome, lesser risk to term infants.
is	negative bacil ureaplasma and Polymicrobial Bacteroides, <i>Prevotella</i> <i>bivius</i> , Group B, Group	anaerobes, usually Ampicillin 500 mg QID + Metronidazole	teicoplanin and cefoperazone- sulbactum If patient is not in sepsis then IV Ampicillin	unfavourable neurologi outcome, lesser risk to term infants.
is	negative bacil ureaplasma and Polymicrobial Bacteroides, <i>Prevotella</i> <i>bivius</i> , Group B, Group	anaerobes, usually Ampicillin 500 mg QID + Metronidazole	teicoplanin and cefoperazone- sulbactum If patient is not in sepsis then IV Ampicillin Ceftriaxone 2g IV	unfavourable neurologi outcome, lesser risk to term infants.
is	negative bacil ureaplasma and Polymicrobial Bacteroides, <i>Prevotella</i> <i>bivius,</i> Group B, Group A	anaerobes, usually Ampicillin 500 mg QID + Metronidazole	teicoplanin and cefoperazone- sulbactum If patient is not in sepsis then IV Ampicillin Ceftriaxone 2g IV	unfavourable neurologi outcome, lesser risk to term infants.
is	negative bacil ureaplasma and Polymicrobial Bacteroides, <i>Prevotella</i> <i>bivius,</i> Group B, Group A Streptococcus,	anaerobes, usually Ampicillin 500 mg QID + Metronidazole 500mg IV TDS if patient has not	teicoplanin and cefoperazone- sulbactum If patient is not in sepsis then IV Ampicillin Ceftriaxone 2g IV	unfavourable neurologi outcome, lesser risk to term infants.
is	negative bacil ureaplasma and Polymicrobial Bacteroides, <i>Prevotella</i> <i>bivius</i> , Group B, Group A Streptococcus, Enterobactereace	anaerobes, usually Ampicillin 500 mg QID + Metronidazole 500mg IV TDS if patient has not taken any prior	teicoplanin and cefoperazone- sulbactum If patient is not in sepsis then IV Ampicillin Ceftriaxone 2g IV	unfavourable neurologi outcome, lesser risk to term infants.
is	negative bacil ureaplasma and Polymicrobial Bacteroides, <i>Prevotella</i> <i>bivius</i> , Group B, Group A Streptococcus, Enterobactereace	anaerobes, usually Ampicillin 500 mg QID + Metronidazole 500mg IV TDS if patient has not	teicoplanin and cefoperazone- sulbactum If patient is not in sepsis then IV Ampicillin Ceftriaxone 2g IV	unfavourable neurologi outcome, lesser risk to term infants.
is	negative bacil ureaplasma and Polymicrobial Bacteroides, <i>Prevotella</i> <i>bivius</i> , Group B, Group A Streptococcus, Enterobactereace ae, <i>C</i> .	anaerobes, usually Ampicillin 500 mg QID + Metronidazole 500mg IV TDS if patient has not taken any prior	teicoplanin and cefoperazone- sulbactum If patient is not in sepsis then IV Ampicillin Ceftriaxone 2g IV OD	unfavourable neurologi outcome, lesser risk to term infants.
is	negative bacil ureaplasma and Polymicrobial Bacteroides, <i>Prevotella</i> <i>bivius</i> , Group B, Group A Streptococcus, Enterobactereace ae, <i>C</i> . <i>trachomatis</i> ,	anaerobes, usually Ampicillin 500 mg QID + Metronidazole 500mg IV TDS if patient has not taken any prior antibiotic (start	teicoplanin and cefoperazone- sulbactum If patient is not in sepsis then IV Ampicillin Ceftriaxone 2g IV OD	unfavourable neurologi outcome, lesser risk to term infants.
is	negative bacil ureaplasma and Polymicrobial Bacteroides, <i>Prevotella</i> <i>bivius</i> , Group B, Group A Streptococcus, Enterobactereace ae, <i>C</i> . <i>trachomatis,</i> <i>Clostridium</i>	Ampicillin 500 mg QID + Metronidazole 500mg IV TDS if patient has not taken any prior antibiotic (start antibiotic after	teicoplanin and cefoperazone- sulbactum If patient is not in sepsis then IV Ampicillin Ceftriaxone 2g IV OD	unfavourable neurologi outcome, lesser risk to term infants.

1	partially treated	
	with antibiotics,	
	send blood	
	cultures and start	
	Piperacillin-	
	Tazobactam or	
	Cefoperazone-	
	sulbactam till the	
	sensitivity report	
	is available.	

Endomyometritis	Bacteroides,		Same as above.	
and Septic Pelvic				
	Group B, Group A			
	Streptococcus,			
	Enterobactereaceae,			
	C. trachomatis,			
	Clostridium			
	Ciosiriaiam			
	perfringens			
Obstetric Sepsis	Group A beta-	If patient is in shock		
during pregnancy	haemolytic	and blood culture		
	Streptococcus,	reports are pending,		
		then start		
	<i>E.coli</i> , anaerobes.	Piperacillin-		
		Tazobactam or		
		Cefoperazone-		
		sulbactam till the		
		sensitivity report is		
		available and		
		modify as per the		
		report. If patient has		
		only fever, with no		
		features of severe		
		sepsis start		
		amoxicillin		
		clavulanate oral		
		625TDS/IV 1.2		
		gm TDS Or		
		Ceftriaxone 2gm IV		
		OD+		
		Metronidazole		
		500mg IV TDS		
		+/-gentamicin		
		7mg/kg/day OD if		
		admission needed.		
		MRSA cover may		
		be required if		
		suspected or		
		colonized		
		(Vancomycin/		
		Teicolaninp)		

Obstetric	Sepsis S. py	ogenes,	Same as above	Sources of sepsis	5	
following pregnancy	Е. со	li,		outside Genital tract Mastitis	l	
	S. au	reus		UTI		
	S. Metic	<i>pneumoniae</i> illin-resistant	,	Pneumonia		
	S. au	reus (MRSA),		Skin and soft tissue (IV site		
	C. sej	pticum &		surgical site. drain site etc.)	,	
	Morg	anella morganii				
Syphillis					Refer to program guidelines	STD
Tuberculosis	inSimil	ar to NON	Please refer RNTCF	guideline	Very small	chance
pregnancy		GNANT			of	ſ
	popu	lation with	WHO has advocated line drugs are	d that, all the first	transmission infection to fe	of etus.

	-	ssafe in pregnancy and can be tused except streptomycin. SM
	and chapter 8)	
		Mother and baby should stay together and the baby shouldLate diagnosis can predispos continue to breastfeed. to LBW, prematurity.
		Pyridoxine supplementation is recommended for all pregnant or breastfeeding women taking
		isoniazid as well as to neonate who are being breast fed by mothers taking INH.
VIRAL INFECTIONS	S (NO ANTIBIOT	who are being breast fed by mothers taking INH. TICS TO BE GIVEN)
VIRAL INFECTIONS Influenza Ir pregnancy (seasona And H1N1)	(NO ANTIBIOT	who are being breast fed by mothers taking INH. FICS TO BE GIVEN) Tendency for Direct fetal infection rare severe including premature labor

Higher doses
commonly used in
non pregnant
population (150
mg) are not
recommended in
pregnancy due to
safety concerns.
4.
Chemoprophylaxis
can be used in
significant

	exposures.
	5. Live (nasal Vaccine) is contraindicated in pregnancy.
Varicella	>20 wks of gestation, VZIG should be offered to Chickenpox during presenting within 24susceptible women < 10 days of pregnancy does not justify hours of the onset of the exposure. VZIG has no role termination without prior the rash, in treatment once the rash prenatal diagnosis as appears. only.
	Aciclovir 800mg Oral 5 times a day IV acyclovir recommended for the treatment of severe complications, > 24 hrs from the onset of rash, antivirals are not found to be useful.

PARASITIC INFECT	IONS		
Acute Toxoplasmosis in pregnancy		<18 weeks gestation at diagnosis Spiramycin 1 gm Oral qid until 16-18 weeks/Pyrimathamine + sulphadizine. Alternate every two weeks–	

weeks gestation and nted fetal infection by amniotic fluid PCR. namine 50 mg Oral BD x 2 n 50 mg OD
azine 75 mg/kg Oral x 1 n 50mg/kg bd
Acid (10-20 mg Oral daily) imum of 4 weeks or for of pregnancy.
n

GENITAL TRACT INFECTIONS

Candidiasis	Candida species	Fluconazole oral 150 mg singleNon-pregnant-
		dose For milder cases-
		Intravaginal agents as creams or suppositories clotrimazole, episodes/year) 6 miconazole, nystatin. Intravaginal azoles, single dose to 7-14 days. (4 or more months suppressive treatment with fluconazole 150 mg oral once a week or clotrimazole vaginal
		suppositories 500 mg once a week.
Bacterial vagine	osis Polymicrobial	Metronidazole500mg Oral BD x 7Treat the partner. days
		Or metronidazole vaginal gel 1 HS x 5 days Or Tinidazole 2 g orally

		ODx 3 days Or 2% Clindamycin	
		Vaginal cream 5 gm HS x 5 days	
Trichimoniasis	Trichomonas vaginalis	Metronidazole 2 gm single dose or	
		500 mg Oral BD X 7 days or	
			Treat sexual partner
			with metronidazole 2
			gm single dose
		Tinidazole 2 gm Oral single	
		doseFor treatment failure	
		– retreat with Metronidazole 500	
		mg Oral BD X 7 Days, if 2nd	
		failure Metronidazole 2 gm Oral	
		OD X 3- 5 days	
		OD A 3- 3 days	
Cervicitis		Ceftriaxone 250 mg IM Single	
		dose + Azithromycin 1 gm single	
/Urethritis	Dolumiarahial	dose OR Doxycycline 100mg BD x	
		7 day	
Mucopurulent			
gonoccocal			
Pelvic	S. aureus,	Outpatient treatment	Drainage of tubo-
Inflammatory	Enterobacteriação		overien ebscess
Disease	concessi condenelle	Ceftriaxone 250 mg IM/IV single	whomewer indicated
(Salpingitis &	8, 8	dose plus +/- Metronidazole 500	Evaluate and treat sex
(~~~ FB >		mg BD x 14 days Plus	partner
tubo-ovarian		Doxycycline 100 mg BD x 14	
abscess)		Days	
		Inpatient Treatment Clindamycin	
		+ceftriaxone till patient admitted	
		then change to OPD treatment	
Mastitis without	S. aureus	Amoxycillin	
abscess		clavulunate/Cephalexin 500 mg	
aDSCC55		QID/ OR Ceftriaxone 2 gm OD OR	
		QID/ OK Celulaxolle 2 glil OD OK	
		MRSA- based on sensitivities Add	
		Clindamycin 300 QID or	
		Vancomycin I gm IV 12 hourly	
		/teicoplanin 12mg/kg IV 12 hourly	
		x 3 doses followed by 6 once daily	
		IV	

Mastitis with	Drainage with antibiotic cover for
abscess	MRSA
	Clindamycin 300 QID or
	Vancomycin 15mg/kg IV 12 hourly (maximum 1gm 12 hourly)/teicoplanin 12mg/kg IV 12 hourly x 3 doses followed by 6 mg once daily IV

BONES AND JOINT INFECTIONS

	Likely causative Organisms	Empiric antibiotics	Alternative antibiotics	Comments
osteomyelitis OR Septic arthritis	<i>Streptococcus pyogenes</i> Enterobacteriaceae	Ceftriaxone 2g IV OD Followed by Oral therapy by Cloxacillin 500mg q 8h Or Cephalexin 500mg q 6h	tazobactam 4.5gm IV q 6h or Cefoperazone- sulbactam 3gm IV q 12h AND Clindamycin	fluid/bone biopsy
				Duration: 4-6 weeks (From initiation or last major debridement)
Chronic		No empiric therapy		Definitive
Osteomyelitis				treatmentguided by
OR				bone/synovial biopsy
Chronic synovitis				culture.
				Treat for 6 weeks
				minimum
				Investigate for TB,
				Nocardia, fungi.
				Extensive surgical
				debridement.
				Total duration of
				treatment depends on

			the
			joint and the organism.
			Choose antibiotic based
			on sensitivity.
Prosthetic joint	Coagulase	Ceftriaxone 2g IV OD.	4 weeks
	negative	Add	
infection	staphylococci,	Vancomycin1gm IV BD or	
	Staphylococcus	Teicoplanin 800mg x 3	
	<i>aureus</i> ,Streptococ ci	doses followed by 400mg	
	Gram-negative bacilli,	Once daily	
	Enterococcus,		
	Anaerobes		

4 <u>FUNGAL INFECTIONS</u>

Routine antifungal prophylactic therapy in critically ill patients is NOT recommended. Fungal therapy is usually started based on positive cultures or systemic evidence of fungal infection. It is advised to take paired cultures if fungal infection is suspected. Evidence includes persistent sepsis / SIRS despite broad spectrum antibiotic (exclude sepsis, abscess, drug fever, DVT etc). Treat according to identification and antifungal sensitivity of Candida isolate.

Fluconazole IV/oral 800 mg OD first day (12mg/kg) and then 400 mg OD (6mg/kg from second day) if fluconazole naïve or sensitive

Or

 2^{nd} line Liposomal Amphotericin B (for *Candida krusei* and *C.glabrata* as inherently resistant to Fluconazole.) or Caspofungin (As Caspofungin is inherently inactive against Zygomycetes, Cryptococcus, Fusarium and Trichosporon Spp) Liposomal Amphotericin B IV 3mg/kg OD or Caspofungin dose: IV 70mg on Day 1 (loading), 50mg OD (<80kg) or 70mg OD (if >80kg) thereafter.Moderate to severe hepatic dysfunction: reduce the subsequent daily dose to 35mg OD. Check for drug interactions.

To be decided by Microbiologist/ID physician based on patient's hepatic / renal functions/Severity of infection /drug interactions e.g. rifampicin, carbamazepine, phenytoin, efavirenz, nevirapine, cyclosporin, dexamethasone, tacrolimus etc.

<u>4 SURGICAL ANTIMICROBIAL PROPHYLAXIS</u>

To be administered within 1 hr before the surgical incision.

Single dose is recommended. Consider for second intra-operative dosein prolong surgery based on the choice of antibiotic used for prophylaxis.

Prophylaxis should **not** be given beyond surgery duration (except for cardiothoracic surgery, up to 48 hours permissible)

Choice of the prophylaxis should be based on the local antibiogram.

SURGERY	MEDICATION							
Breast	Inj.Cefazolin 2gm	or Inj.Cefuro	xime 1	.5gm	IV sta	at		
Gastroduodenal & biliary	Inj.Cefaperazone-	Sulbactam	2gm	IV	stat	&	BD	for

31 | P a g e

	24hrs(maximum)
ERCP	Inj.Piperacillin-Tazobactum 4.5gm or Inj.Cefaperazone- Sulbactam 2gm IV stat
Cardiothoracic	Inj.Cefuroxime 1.5gm IV stat & BD for 48hrs
Colonic surgery	Inj.Cefaperazone- Sulbactam 2gm IV stat & BD for 24hrs(maximum)
Abdominal surgery (hernia) Inj.Cefazolin 2gm or Inj.Cefuroxime 1.5gm IV stat
Head & Neck/ ENT	Inj.Cefazolin 2gm IV stat
Neurosurgery	Inj.Cefazolin 2gm or Inj.Cefuroxime 1.5gm IV stat
Obstetrics& Gynecology	Inj.Cefuroxime 1.5gm IV stat
	Inj.Cefuroxime 1.5gm IV stat & BD for 24 hrs(maximum) or
Orthopaedic	Inj.Cefazolin 2gm IV stat
	Open reduction of closed fracture with internal fixation-
	Inj.Cefuroxime 1.5gm IV stat and q 12h or Inj.Cefazolin 2gm
	IV stat and q 12h for 24 hrs
Trauma	Inj.Cefuroxime 1.5gm IV stat and q 12h (for 24 hrs)
	or Inj.Ceftriaxone 2gm IV OD
Urologic procedures	Antibiotics only to patients with documented bacteriuria
Trans- rectal prostat surgery	icInj.Cefaperazone- Sulbactam 2gm IV stat

Good Practices

Send for the appropriate investigations in all these infections as recommended. These are the minimum required for diagnosis, prognosis and follow up of these infections.

- All antibiotic initiations would be done after sending appropriate cultures. Rapid tests, such as Gram stain, can help determine therapeutic choices when empiric therapy is required.
- Change in antibiotic would be done after sending fresh cultures
- Follow the Hospital policy when choosing antimicrobial therapy whenever possible. If alternatives as chosen, document the reason in the case records.
- Check for factors which will affect drug choice & dose, e.g., renal function, interactions, allergy. Check that the appropriate dose is prescribed. If uncertain, contact Infectious disease physician, Pharmacy, or check in the formulary.
- The need for antimicrobial therapy should be reviewed on a daily basis. For most infections 5 7 days of antimicrobial therapy is sufficient (simple UTIs can be adequately treated with 3 days of antibiotic).
- All IV antibiotics may only be given for 48 72 hours without review and consideration of
 oral alternatives. New microbiological or other information (e.g. fever defervescence for at
 least 24h, marked clinical improvement; low CRP) should at this stage often permit a switch
 to oral antibiotic(s), or switch to an IV narrow spectrum alternative, or cessation of
 antibiotics (no infection present).
- Once culture reports are available, the physician shall step down to the narrowest spectrum, most efficacious and most cost-effective option. If there is no step down availed, the reason shall be documented and is subjected to clinical audit.
- Differentiation between contamination, colonization and infection is important to prevent overuse of antibiotics.

Monitoring Sheets

	Name of the Hospital
	High End Antibiotic Monitoring Form
Imiper	enem, doripenem nem, etrapenem in, tigecycline Intercollanin vancomycin Intercollanin vancomycin Intercollanin vancomycin
Antibi	otic used:
Indica	tion:
Date s	tarted:
REVI	EW
•	Second day:
•	Fifth day:
•	Tenth day:
Comm	ents by Infection Control team:
Feed b	ack given to the doctor (if necessary):

High-end Antibiotic Monitoring Sheet

Surgical Prophylaxis Monitoring Sheet

surgical antibiotic prop	phylaxis monitoring sheet
Patient Details	Date of Admission: Name of Surgeon:
Date of Surgery:	
Type of surgery:	
Date of Discharge:	
Prophylactic antibiotic used:	
Dose:	
Duration:	
Reason if antibiotic give	en for more than the recommended
duration:	
Signature of the Doctor	
Comments by Infection control Te	am

References

Infection Control Manual. (2018). Retrieved from <u>https://uphssp.org.in/Tenders/InfectionControlManual.pdf</u>

- National Treatment Guidelines for Antimicrobial Use in Infectious Diseases. (2016). NATIONAL CENTRE FOR DISEASE CONTROL. Retrieved from <u>file:///G:/Desktop/antibiotics/AMR_guideline7001495889.pdf</u>
- NATIONAL POLICY FOR CONTAINMENT OF ANTIMICROBIAL RESISTANCE INDIA.(2011).Directorate General of Health Services. Retrived from <u>file:///G:/Desktop/Antimicribial%20Policy/antimicrobial%20policy/3203490350abpolicy%20</u> (1).pdf
- NHS. (2019). Overview Antibiotics. Retrieved from https://www.nhs.uk/conditions/antibiotics/
- WHO. (2012). Prevention of hospital-acquired infections: A practical guide. 2nd edition. Retrieved from<u>https://www.who.int/csr/resources/publications/drugresist/WHO_CDS_CSR_EPH_2002</u>_12/en/